Merrimack Pharmaceuticals Inc. (MACK)

4.24
NASDAQ : Health Technology
Prev Close 4.20
Day Low/High 4.15 / 4.26
52 Wk Low/High 3.34 / 11.70
Avg Volume 94.60K
Exchange NASDAQ
Shares Outstanding 13.34M
Market Cap 56.04M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121 In Patients With Non-Small Cell Lung Cancer Due To Futility

Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121 In Patients With Non-Small Cell Lung Cancer Due To Futility

- MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC) -

Merrimack Receives $5 Million Milestone Payment From Shire

Merrimack Receives $5 Million Milestone Payment From Shire

CAMBRIDGE, Mass., Sept.

Merrimack Reports Second Quarter 2018 Financial Results

Merrimack Reports Second Quarter 2018 Financial Results

- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources -

Merrimack Announces Timing Of Second Quarter 2018 Investor Conference Call

Merrimack Announces Timing Of Second Quarter 2018 Investor Conference Call

CAMBRIDGE, Mass., July 31, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.

Merrimack Secures $25 Million Debt Facility With Hercules Capital

Merrimack Secures $25 Million Debt Facility With Hercules Capital

- Non-dilutive financing strengthens cash position -

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141 In Front-Line Metastatic Pancreatic Cancer

Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141 In Front-Line Metastatic Pancreatic Cancer

- CARRIE study did not meet primary or secondary endpoints -

Merrimack Pharmaceuticals is Now Oversold (MACK)

Merrimack Pharmaceuticals is Now Oversold (MACK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Monday Option Activity: MACK, PFPT, RDNT

Notable Monday Option Activity: MACK, PFPT, RDNT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Merrimack Pharmaceuticals Inc , where a total of 582 contracts have traded so far, representing approximately 58,200 underlying shares. That amounts to about 53.7% of MACK's average daily trading volume over the past month of 108,375 shares.

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Verastem Shares Are Exploding 50% -- Here's Why

Verastem Shares Are Exploding 50% -- Here's Why

The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

First Week Of MACK May 19th Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the May 19th expiration.

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

First Week of MACK April 21st Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Dow Steps Back From 20,000 as Crude Selloff Weighs on Energy Sector

Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.